Biocon Limited
20th KM Hosur Road
Electronics City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423
CIN : L24234KA1978PLC003417

www.biocon.com

Date of submission: 02nd May, 2018

To The Secretary Listing Department BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523	To The Secretary Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 Scrip Code- BIOCON

Dear Sir/Madam,

Sub: Biocon Regulatory Audit Update

.

Ref: Regulations 30 of SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015.

Pursuant to Regulation 30 of the SEBI LODR Regulations, 2015, please find below the company statement on the subject matter:

"The US-FDA has completed a pre-approval inspection of our sterile drug product manufacturing facility in Bangalore this week and issued a Form 483 with 7 observations. The observations are largely procedural and aimed at continuous improvement. We will respond to the FDA with a corrective and preventive action plan in a timely manner.

We have also this week received the preliminary report from the European Regulator post inspection of our sterile drug product facility in Bangalore in March 2018. The report lists 6 major observations with no observation classified as critical. We will submit a corrective and preventive action plan to the European inspection agency within the stipulated time period." - Biocon Spokesperson

We request you to kindly take this is your record as per the requirement of Listing Regulations and oblige.

Thanking You,
Yours faithfully
For Biocon Limited

Akhilesh Nand
Chief Compliance Officer